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ABSTRACT 
Objectives: S100A8/A9 (calprotectin) has shown promise as a biomarker for predicting relapse in 
AAV. This study investigated serum S100A8/A9 levels as a biomarker predicting future relapse in a 
large cohort of patients with severe ANCA-associated vasculitis (AAV). 
Methods:  Serum levels of S100A8/A9 were measured at baseline, months 2, and 6 following 
treatment initiation in 144 patients in the RAVE trial (cyclophosphamide/azathioprine vs. rituximab 
for induction of remission) who attained complete remission.   
Results: Patients were divided into 4 groups: PR3-ANCA with (n=37), and without (n=56) relapse, and 
MPO-ANCA with (n=6) and without (n=45) relapse. Serum S100A8/A9 levels decreased in all groups 
during the first 6 months of treatment. The percentage reduction from baseline to month 2 was 
significantly different between relapsers and non-relapsers in the PR3-AAV group (p=0.046). A 
significantly higher risk of relapse was associated with an increase in S100A8/A9 between baseline 
and month 2 (p=0.006) and baseline and month 6 (p=0.0099) for all patients. Subgroup analysis 
demonstrated it was patients treated with rituximab and who increased levels of S100A8/A9 who 
were at greatest risk of future relapse (p=0.028). 
Conclusion: An increase in serum S100A8/A9 by month 2 or 6 compared to baseline identifies a 
subgroup of PR3-ANCA patients treated with rituximab at higher risk of relapse by 18 months. As 
rituximab is increasingly used for remission induction in relapsing PR3-ANCA patients, S100A8/A9 
may assist in identifying those patients requiring more intensive or prolonged treatment. 
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INTRODUCTION 
Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis are classified as anti-neutrophil 
cytoplasm antibody (ANCA)- associated vasculitis (AAV), commonly affecting the kidneys, lungs, and 
other organs(1).  ANCA is detected in a significant proportion of patients with active GPA as well as 
microscopic polyangiitis, while some patients may be ANCA-negative(2, 3). Although serial ANCA 
testing is often performed to help assess disease activity or to predict relapse, its usefulness is 
controversial(4). Other potential biomarkers of systemic inflammation have been identified to assist 
in distinguishing active vasculitis from inactive disease, but not for predicting relapse(5). More 
recently, a transcriptional profiling approach identified a subset of CD8+ T cell genes associated with 
a poor prognosis in various autoimmune diseases, and is therefore a potential biomarker in AAV, but 
has yet to be validated(6).   
 
Remission followed by relapse is common in patients with AAV, especially those patients positive for 
PR3-ANCA, with reported relapse rates of up to 55% within the first 3 years of treatment(7). The risk 
of relapse continues in the long-term follow-up of these patients, and a proportion of patients 
progress to end-stage renal disease (ESRD)(8), which may represent progressive chronic kidney 
disease or ongoing relapsing vasculitis. However, since reliable biomarkers for relapse have not yet 
been found, therapy is not highly customised for individual patients. Therefore, similar regimens are 
used for many patients, potentially exposing some to unnecessary prolonged immunosuppression, 
while others who could benefit from more intense treatment may not be easily identified.   
 
S100A8 and S100A9 are members of the S100 family of proteins that form a heterodimer of 
S100A8/A9 (termed calprotectin), which is expressed in neutrophils, monocytes, and early-
differentiated macrophages but not resident tissue macrophages(9, 10). S100A8/A9 heterodimer is 
an endogenous ligand of toll-like receptor-4 (TLR4)(11) as well as the receptor for advanced 
glycation end-products (RAGE)(12, 13). S100A8/A9 is secreted locally at the site of inflammation by 
phagocytes, where it has a number of autocrine and paracrine pro-inflammatory effects on 
phagocytes(14-16), and the endothelium(17, 18), both of which are implicated in the pathogenesis 
of vasculitis. Serum levels of the heterodimer S100A8/A9 are increased in several inflammatory and 
autoimmune conditions, including juvenile idiopathic arthritis, where levels predicted disease 
relapse(19, 20), rheumatoid arthritis(16, 21), systemic lupus erythematosus (SLE)(22), and Kawasaki 
disease(23). Measurement of faecal calprotectin is routinely performed to detect mucosal 
inflammation in inflammatory bowel disease(24). 
 
We previously demonstrated that patients with active generalised AAV had elevated serum 
S100A8/A9 levels compared to patients in remission and healthy controls. Patients with focal and 
crescentic glomerulonephritis demonstrated glomerular infiltration of S100A8/A9 positive 
macrophages. Additionally, in a cohort of patients with early limited systemic disease, persistently 
elevated S100A8/A9 levels despite immunosuppressive treatment, were found in patients who went 
on to relapse(25). In that analysis we did not have available pre-treatment samples for analysis, so 
we concluded that failure to suppress S100A8/A9 whilst on treatment was associated with relapse. 
To validate this study, we proceeded to measure levels of serum S100A8/A9 in a large number of 
patients with severe AAV enrolled in the Rituximab in ANCA-Associated Vasculitis (RAVE) trial, and 
investigate whether a failure to suppress S100A8/A9 with conventional treatment was predictive of 
future disease flares.  
 
METHODS 
Trial details 
The RAVE trial was a multi-center, randomized, double-blind trial comparing rituximab with standard 
cytotoxic immunosuppression in patients with severe ANCA associated vasculitis for the induction of 
remission by 6 months. Patients were eligible if they had a new or relapsing diagnosis of GPA or 
MPA, positive serum assays for PR3-ANCA or MPO-ANCA and severe manifestations of disease. 
Standard immunosuppression for induction therapy consisted of oral cyclophosphamide (CYC) and 
glucocorticoids, compared to the investigational therapy of rituximab and glucocorticoids. Those 
patients in the CYC group were switched to maintenance therapy with azathioprine if complete 
remission was achieved between month 4 to 6. Both groups received the same reducing 
glucocorticoid regime. The primary end-point was defined as a Birmingham Vasculitis Activity Score 
for Wegener’s Granulomatosis (BVAS/WG) of 0 and the successful discontinuation of prednisone. 
Disease flare was defined as an increase in BVAS/WG of 1 point or more. The 18 month follow-up 
data was also published(26).  
 
Study design 
Serum from 188 patients was obtained for this study. The time-points included serum at baseline 
(time 0), and months 1, 2, and 6 after the start of treatment. The primary goal was to determine the 
level of serum S100A8/A9 at these different time points, and the relative changes in serum levels 
over time, and correlate these values with the duration of complete remission and time to relapse. 
For the purpose of this analysis, relapse episodes were defined as a disease flare from month 6 
onwards. Those patients who were classified as not entering complete remission during the study 
were excluded from analysis. Additional clinical and laboratory data was obtained from the trial 
database.  
 
Measurement of serum S100A8/A9 
Samples were stored at -80C until analysis. S100A8/A9 was analysed by sandwich enzyme-linked 
immunosorbent assay (ELISA) as per manufacturer’s instructions (BioLegend). 
 
Statistical analysis 
All statistics were performed using GraphPad Prism 6.0 (GraphPad Software, San Diego California, 
USA) and Stata v11 (StataCorp LP, Texas, US). Variables were log transformed where distributions 
were skewed. Non-parametric tests of significance were applied. For comparing 2 groups, Mann-
Whitney U test was used. To compare the absolute values at subsequent time-points compared to 
baseline, a mixed-effects model was utilised. Correlations were assessed using the non-parametric 
Spearman rank correlation analysis. Statistical  significance  was defined as p<0.05. For relapse-free 
survival analysis, Bonferroni correction was used for multiple comparisons with significance defined 
at p<0.025.   
 
Risk of relapse was investigated using Kaplan-Meier survival analysis and the influence of baseline 
renal involvement and change in ANCA titre on the relationship between changes in S100A8/A9 and 
relapse examined using the Cox proportional hazards approach. This was an exploratory study 
however a post-hoc power calculation using Freedman method suggested there was a 60% power to 
detect the effect size observed in PR3 subjects assuming a probability of relapse of 0.31 in the 
reference group (S100A8/A9 decrease) (without adjustment for multiple comparisons). 
 
To explore the value of change in S100A8/A9 to predict relapse, we developed multivariable 
logistical regression models including clinical and laboratory parameters that might be used in 
clinical practice to assess risk of relapse: age; sex; ethnicity; PR3 ANCA vs MPO ANCA status; baseline 
renal involvement; RAVE treatment arm; CRP; change in ANCA titre (over the same period as change 
in S100A8/A9).  The utility of the addition of change in S100A8/A9 to change in ANCA titre versus 
change in ANCA titre alone as a predictor of relapse was quantified by Receiver operator curves 
(ROC) generated from these logistic regression models.  
 
RESULTS 
Demographics and patient groups 
Patients were divided into 4 groups depending on their ANCA subtype and whether they relapsed 
during the 18 months of follow-up of the trial. For patients to be included in the analysis, they must 
have entered complete remission, as defined by a BVAS/WG of 0 and the successful discontinuation 
of prednisone. Therefore, 44 patients (33 PR3-ANCA and 11 MPO-ANCA) were excluded from 
analysis as these patients did not achieve complete disease remission. 
 
144 patients were included in the analysis (Table 1). 93 PR3-ANCA patients (65%) and 51 MPO-ANCA 
patients (35%). The median age of the patients included was 52.5 years (range 15-92) with 70 (49%) 
female and 74 (51%) male patients. 77 (53%) of the patients had a new diagnosis of AAV at the time 
of enrollment in the study and 67 (47%) patients presented with relapsing disease. 76 (53%) of 
patients had renal involvement at baseline. 68 patients (47%) were in the 
cyclophosphamide/azathioprine arm and 76 patients (53%) were in the rituximab arm. 
 
Serum levels of S100A8/A9 (calprotectin) at the difference time-points 
Serum S100A8/A9 levels significantly decreased from baseline to month 1, 2, and 6 in the whole 
cohort of patients, with median serum S100A8/A9 at baseline 6509 ng/ml (range 1002-92267), 
month 1 4660ng/ml (962-35523; p<0.0001 vs. baseline), months 2 4004 ng/ml (1020-25814;  
p<0.0001 vs. baseline),  and month 6 3141 ng/ml (346-19383; p<0.0001 vs. baseline) (Figure 1(i)). 
The results for within patient change using log S100A8/A9 multilevel model random intercept is 
highly significant at each time point. There was no statistical difference in absolute S100A8/A9 levels 
between MPO-ANCA and PR3-ANCA patients at any time point (Table 2) or between those patients 
who did or did not relapse at each time point, with the exception of a difference between the 
relapsing and non-relapsing PR3-ANCA group at month 2 (p=0.05)(Table 2). In addition, there was no 
difference in the absolute levels of serum S100A8/A9 at any time point between those patients 
presenting with (n=76) or without (n=68) renal involvement.  
 
Change in serum levels of S100A8/A9 at the different time points. 
We then investigated the percentage change of serum S100A8/A9 for individual patients between 
two time-points according to relapse status. As there were only six MPO-ANCA patients who 
relapsed, we focused our analysis on the PR3-ANCA patient cohort. 
 
There was a significant difference in the percentage change in serum S100A8/A9 between the PR3-
ANCA relapsers and non-relapsers at baseline compared to month 2 levels (Figure 1), with relapsing 
patients demonstrating less serum S100A8/A9 suppression. The median change in serum S100A8/A9 
at month 2 compared with baseline was a decrease of 10% in the relapsing groups (IQR -59% to 
+60%), with a significantly greater degree of suppression in the non-relapsing group of 31% (IQR -60 
to -9%)(p<0.0457). Therefore, an increase in serum S100A8/A9 identifies a subset of patients during 
the first 6 months who are at risk of disease relapse during the subsequent 12 months. The relative 
risk for relapse with an increase in S100A8/A9 at month 2 compared to baseline was 1.81 (CI 1.11-
2.93), and at month 6 compared to baseline was 1.76 (CI 1.1-2.83).  Figure 1 (iii) demonstrates the 
mean % change from (i) baseline to month 1, (ii) baseline to month 2 and (iii) baseline to month 6. 
The patients are classified into 4 groups according to relapse status and treatment arm. This data 
demonstrates that those patients treated with rituximab who went onto relapse, increased serum 
S100A8/A9 between the time-points. 
 
Increase in serum levels of S100A8/A9 predicts earlier relapse  
When patients were categorized into whether they had an increase or decrease in serum S100A8/A9 
between 2 time-points, those patients who demonstrated an increase in serum S100A8/A9 from 
baseline to month 2 (p=0.004) and baseline to month 6 (p=0.003), demonstrated significantly earlier 
and more frequent relapses than those patients who suppressed serum S100A8/A9 (Figure 2). 
 
When these groups where divided according to the different treatment arms, it was those patients 
within the rituximab treatment arm with increased levels of serum S100A8/A9 between the time 
points who demonstrated significantly earlier relapses (Figure 3).  
 
Cox-regression analysis was used to determine the risk of a future relapse for the PR3-ANCA 
patients. The increase in ANCA at month 2 compared to baseline was associated with a hazard ratio 
(HR) of 0.85 (CI 0.55-1.13) while the increase in serum S100A8/A9 had a significantly higher HR of 2.2 
(CI 1.17-4.26)(p=0.016). This model was unaffected by whether patients had renal involvement at 
entry into the trial but model fit was improved by the addition of change in ANCA titre.  
 
To further investigate the potential of serum S100A8/A9 as a biomarker to stratify relapse risk in 
patients treated with rituximab early in the induction period multivariable logistic regression models 
were developed. Only addition of change in ANCA titre (over the same time period e.g. 2- or 6-
months compared to baseline) improved model fit. Receiver operator curves (ROC) for change from 
baseline to month 2 demonstrated an AUC of 0.55 for an increase in ANCA and an AUC of 0.77 for 
the combination of an increase in ANCA and serum S100A8/A9 (p=0.028 for a difference between 
curves). At 6 months, the AUC for an increase in ANCA is 0.69, while the combination of increase in 
both ANCA and serum S100A8/A9 generated a higher AUC of 0.75 (p=NS). 
 
New versus relapsing disease 
77 patients at time of inclusion into the trial presented with new disease while 67 presented with 
relapsing disease; these sub-cohorts were then analysed separately. At baseline, those patients 
(MPO-ANCA and PR3-ANCA combined) presenting with new disease had a statistically significant 
higher level of serum S100A8/A9 than those patients presented with relapsing disease, with a 
median level of 7439 ng/ml (1002-92267) compared to 4933 ng/ml (1341-14653)(p=0.0008). There 
was no difference comparing new disease versus relapsing disease at the later time-points. Analysing 
the patients with PR3-ANCA only, there was a significantly greater absolute value of serum 
S100A8/A9 between those patients presenting with new disease compared to relapsing disease at 
baseline (p=0.009), and at month 6 (p=0.029).  
 
Correlations 
Combining the patients with PR3-ANCA and MPO-ANCA, correlations of serum S100A8/A9 with 
clinical parameters were analysed. At baseline, there was a weak correlation between the serum 
levels of S100A8/A9 and C-reactive protein (CRP) [r=0.22 (p=0.016)], total white cell count (WCC) 
[r=0.23 (p=0.01)], and BVAS/WG score [r=0.27 (p=0.002)]. This correlation persisted at month 1, with 
CRP [r=0.24 (P=0.005))] and WCC [r=0.34 p<0.0001)]. However, by month 2 there remained only a 
weak correlation with WCC [r=0.32 (p=0.0002)]. There was no correlation between serum 
S100A8/A9 levels and BVAS/WG at months 1, 2, or 6. 
Comparing the subset of patients with relapsing PR3-ANCA vasculitis, this subset again had a weak 
correlation between serum S100A8/A9 and CRP at baseline (r=0.4)(p=0.017). However at months 1, 
2 and 6 this correlation was not significant. This demonstrates that the traditional markers of 
inflammation and activity such as CRP remain suppressed during remission prior to a future relapse, 
unlike S100A8/A9. 
 
Patients treated with cyclophosphamide/azathioprine had a lower overall WCC at month 1 and 
month 2 compared to those patients treated with rituximab, however, there was no difference in 
the neutrophil and monocyte counts, cells known to express S100A8/A9, at these time points (data 
not shown). 
 
DISCUSSION 
This study demonstrates that S100A8/A9 can help identify those patients with AAV at risk of a future 
disease relapse. Laboratory parameters such as CRP and ANCA titers are often used to assist with 
determining disease activity, however, these measurements have a limited use in helping predict a 
future flare. Data regarding monitoring change in ANCA titre as a marker of future disease activity 
are somewhat inconsistent. Measurement of MPO-ANCA in patients has been reported to be more 
reliable an indicator of relapse or disease activity than those patients positive for PR3-ANCA (4), 
while longitudinal ANCA measurements may have significant benefit in predicting relapse, but 
mostly in those patients with renal involvement(27). However, a previous meta-analysis of 
numerous reports related to ANCA monitoring was unable to draw firm conclusions due to the 
heterogeneity in the methods of differing studies(28), with a more recent meta-analysis 
demonstrating the limited use of serial ANCA measurements(4). It has been clearly demonstrated 
from numerous cohorts that patient with PR3-ANCA are at greater risk of relapse than patients with 
MPO-ANCA (29-31) and these data were confirmed in the RAVE study(32). However, to date no 
alternative biomarker for relapse has been validated for clinical use. A promising gene expression 
profiling approach has identified a novel CD8+ signature, that defines a subgroup of patients (with 
SLE, AAV, and inflammatory bowel disease) at risk of relapse(6), but this requires further validation.  
 
The identification of a biomarker to predict relapse may permit individualization of treatment, such 
that patients who may be at a lower risk of a future disease relapse are exposed to lower levels of 
immunosuppression, with a potentially reduced treatment related morbidity and mortality, while 
those patients who are at increased risk of subsequent flares may be treated with augmented 
therapy which may minimize disease-related morbidity and mortality. Using S100A8/A9 to predict 
relapse has also be demonstrated in juvenile idiopathic arthritis, with an absolute serum level 
measured during disease remission accurately predicting future disease flares(20). 
 
Our current data suggest that it is the change in an individual patient’s level of S100A8/A9 from the 
time of diagnosis that stratifies the patient’s relapse risk. Only a small number of patients with MPO-
ANCA relapsed, therefore it was not possible to draw conclusions regarding the MPO-ANCA positive 
cohort, however, up to 50% of patients with PR3-ANCA had relapsed within 400 days following 
complete remission. Analyzing the PR3-ANCA patient sub-cohort demonstrated that those patients 
who did not relapse during the trial had significantly greater decreases in the level of serum 
S100A8/A9 early during their immunosuppressive therapy. Moreover, those patients who had 
increased levels of serum S100A8/A9 between selected early time points were at a significantly 
greater risk of relapse than those patients who demonstrated decreased levels between these time-
points. This is the first time that we have been able to stratify the risk of relapse within the PR3-
ANCA population.  
 
Interestingly, there was a correlation of serum S100A8/9 levels with BVAS/WG at baseline but this 
correlation was lost at later time points, suggesting that the elevated levels of serum S100A8/A9 
during apparent clinical remission (with a BVAS/WG of 0), may imply a degree of subclinical 
inflammation and a risk of subsequent disease relapse not easily appreciated from clinical 
assessment or more conventional markers. Further analysis demonstrated that it was the patients 
treated with rituximab with failure to suppress serum S100A8/A9 who were at most risk of a future 
relapse, implying that mechanisms of achieving relapse may not all be equivalent, from the point of 
view of disease pathophysiology. A recent study investigating S100A8/A9 (defined as MRP8/14 in 
this study) in rheumatoid arthritis treated with biological agents demonstrated the significant 
decline in S100A8/A9 in patients treated with adalimumab, infliximab and rituximab who responded 
to therapy. Interestingly, in those patients treated with rituximab, the non-responders significantly 
increased serum S100A8/A9 at 16 weeks unlike the non-responders treated with infliximab and 
adalimumab (33). Similar to these data, in juvenile idiopathic arthritis, after the withdrawal of 
methotrexate, levels of S100A8/A9 during remission were significantly higher in those patients who 
went onto relapse (19). 
 
Our results suggest that changes in serum S100A8/A9 may help predict those patients treated with 
rituximab at risk of relapse, with an increase in S100A8/A9 following rituximab therapy putting the 
patients at risk of disease relapse. It does, however, remain unclear why some patients treated with 
cyclophosphamide/azathioprine, with a similar relapse rates as the rituximab group, relapsed 
despite decreases in the serum level of S100A8/A9, and these differences in the biological processes 
surrounding S100A8/9 require further investigation. This is similar to a recent study using the same 
cohort of patients in which the risk of relapse following an increase in PR3-ANCA was higher in the 
rituximab treated group than the group treated with cyclophosphamide/azathioprine. Additionally, 
in this study, patients with renal disease or alveolar haemorrhage, the rise in ANCA titer had greater 
predictive value for subsequent relapse (34).  
In our study, cyclophosphamide resulted in suppression of S100A8/A9 in patients who did proceed 
to relapse suggesting there is a difference in disease relapse mechanisms between those patients 
treated with more selective B-cell depletion therapy compared to those patients treated with 
cyclophosphamide.  
Finally, in those patients at risk of relapse, as determined by consecutive measurement of serum 
S100A8/A9 and calculation of % change in S100A8/A9, it may be tempting to suggest augmented 
immunosuppression, or at least, that they are not subjected to treatment minimization or 
withdrawal; this approach should be tested in a prospective manner to confirm the utility of our 
data.  
  
Table 1: Baseline patient characteristics 
 
 
Baseline characteristics of the patients at baseline upon entry into the RAVE trial [(W) White, (B) 
Black, (O) Other]. The patients were divided into 4 groups based on their relapse status at the end of 
the trial and the type of ANCA present. 
 
 
 
 
 
 
 
 
 
 All patients Anti-PR3 
non-relapse 
Anti-PR3 
relapse 
Anti-MPO 
non-relapse 
Anti-MPO-
relapse 
Total number of 
patients 
144 56 37 45 6 
Age years 
(median/range) 
52.5 (15-92) 51.5 (17-77) 51 (15-74) 55 (16-92) 75.5 (48-78) 
Female/Male 70/74 22/34 16/21 29/16 3/3 
Ethnicity W134, B6,O4 W50, B3, O3 W37 W42, B3 W5, O1 
New diagnosis at 
presentation 
77 
(53%) 
28 12 35 2 
Relapse at 
presentation 
67 
(47%) 
28 25 10 4 
Renal failure at 
Baseline 
76 
(53%) 
27 15 31 3 
BVAS at baseline 
(median/range) 
8 (3-16) 10 (4-15) 7.5 (3-14) 8 (4-16) 10 (6-12) 
Cyclophosphamide 68 26 17 23 2 
Rituximab 76 30 20 22 4 
 Table 2: Serum S100A8/A9 levels in patients according to relapse status and ANCA subtype at 
different timepoints. Serum levels are reported with the median and range. Values analysed using 
Mann-Whitney U-paired t-test. 
 
 
 
 
 
 
  
Median/ 
Range 
All Anti-PR3 non-
relapse 
Anti-PR3 
relapse 
P 
 Value 
Anti-MPO 
non-relapse 
Anti-MPO-
relapse 
P 
 value 
Baseline 
ng/ml 
6509  
(1002-92267) 
6304 
(1894-92267) 
5522  
(1341-29920) 
p=0.66 6869  
(1002-29653) 
8385  
(3174-13639) 
p=0.56 
month 1 
ng/ml 
4660  
(962-35523) 
4914 
(1463-18248) 
4649  
(1317-26071) 
p=0.65 4109  
(1077-35523) 
4632  
(962.2-18290) 
p=0.8 
month 2 
ng/ml 
4004  
(1020-25814) 
3900 
(1112-9413) 
4898  
(1798-19152) 
p=0.05 3481  
(1020-19037) 
2651  
(1364-25814) 
p=0.4 
month 6 
ng/ml 
3141  
(346-19383) 
2941 
(711-19383) 
3976  
(751-10517) 
p=0.47 3070  
(346-12818) 
4202  
(944-18839) 
p=0.17 
month 12 
ng/ml 
3428  
(408-24235) 
3283 
(408-15033) 
3304  
(513-24235) 
p=0.80 3428 
(1021-13070) 
3707  
(2784-4694) 
p=0.85 
Figures 
 
Figure 1 
 
 
Graphs to demonstrate the % change in serum S100A8/A9. (i) Demonstrates the absolute values of 
serum S100A8/A9 at each time point in all patients (n=144): baseline, month 1, month 2 and month 
6 with significant decreases in the value compared to baseline [all p<0.0001] (ii) shows the results 
comparing the % change in  the PR3-ANCA patients serum levels at month 2 compared to baseline. 
The median change in serum S100A8/A9 at month 2 compared to baseline was a decrease of 10% in 
the relapsing groups (IQR -59% to +60%), and a decrease of 31% in the non-relapsing group (IQR -60 
to -9%)(p=0.046)[Mann-Whitney U-paired t-test].(iii) Graph demonstrates the % change in PR3-
ANCA patients divided into 4 groups (RTX relapse and non-relapse, CYC relapse and non-relapse). 
The % change in S100A8/A9 is baseline compared to month 1 (M1), month 2 (M2) and month 6 
(M6). 
 
 
 
 
 
 
Figure 2 
 
 
 
Graphs (i) and (ii) are Kaplan-Meier survival curves of the PR3-ANCA patients remaining relapse-free. 
Times in days represents the duration of complete remission. The data has been adjusted for 
multiple comparisons and significance defined as p<0.025. The patients are divided into 2 groups: 
those with a decrease  (solid line) and those who had an increase (dotted line) in serum S100A8/A9 
between the following time-points: (i) Baseline to month 2 data: (ii) Baseline to month 6. The 
numbers represent those patients remaining relapse free during follow-up. There is a significant 
difference in relapse-free survival, with those patients increasing serum S100A8/A9 having a 
significantly lower relapse-free survival. (i) baseline to month 2 (p= 0.0043), (ii) baseline to month 6 
(p=0.0029). Numbers at risk included. 
 
 
 
 
 
Figure 3 
 
 
Relapse-free survival divided into the trial treatment groups of all the patients. The x-axis 
demonstrates days follow-up from 6 months. The patients are divided into 4 groups depending on 
treatment arm and relapse status. [Blue solid line= patients treated with rituximab with an increase 
in S100S8/A9][blue dotted line= patients treated with rituximab with no increase in 
S100A8/A9][black solid line= patients treated with cyclophosphamide with an increase in 
S100S8/A9][black dotted line= patients treated with cyclophosphamide with no increase in 
S100A8/A9]. The numbers on the graph represent the number of patients free of relapses 
categorized into treatment arm and whether there was an increase or decrease in S100A8/A9. 
Patients treated with rituximab who increased S100A8/A9 demonstrate significantly more relapses 
than patients with a decrease in S100A8/A9.(i) baseline to month 2 (p=0.006) (ii) baseline to month 6 
(p=0.028). 
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